A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies - Université Claude Bernard Lyon 1 Access content directly
Journal Articles Blood Year : 2016

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

H. S. Walter
  • Function : Author
S. A. Rule
  • Function : Author
M. J. S. Dyer
  • Function : Author
C. Jones
  • Function : Author
B. Cazin
  • Function : Author
N. Shah
  • Function : Author
C. V. Hutchinson
  • Function : Author
H. Honda
  • Function : Author
K. Duffy
  • Function : Author
J. Birkett
  • Function : Author
V. Jamieson
  • Function : Author
N. Courtenay-Luck
  • Function : Author
T. Yoshizawa
  • Function : Author
J. Sharpe
  • Function : Author
T. Ohno
  • Function : Author
S. Abe
A. Nishimura
  • Function : Author
F. Morschhauser
  • Function : Author
C. Fegan
  • Function : Author

Dates and versions

hal-01796198 , version 1 (19-05-2018)

Identifiers

Cite

H. S. Walter, S. A. Rule, M. J. S. Dyer, L. Karlin, C. Jones, et al.. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood, 2016, 127 (4), pp.411-419. ⟨10.1182/blood-2015-08-664086⟩. ⟨hal-01796198⟩
52 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More